Digest Network Come funziona
Network
/
Società
LI
Non verificato

LIB Therapeutics Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaIndustriaSalute

10 comunicati stampa

Guarda tutti i comunicati
28/09/2026
Mercato del lavoro
Industria
Scienza
Igiene alimentare
Cardiologia
Biotecnologia
Sanità
Salute
Farmaceutica
LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
26/05/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Eventi
Industria
LIB Therapeutics Announces Results from Presentations on LEROCHOL® (lerodalcibep-liga) at the 2026 European Atherosclerosis Society Meeting in Athens, May 24-26, 2026
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
30/03/2026
Eventi
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
LIB Therapeutics Announces Results from Presentations on LEROCHOL® at 2026 American College of Cardiology meeting in New Orleans March 28-29, 2026
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
15/12/2025
Industria
Scienza
Igiene alimentare
Medicina - Varie
Cardiologia
Biotecnologia
Salute
Farmaceutica
U.S. Food and Drug Administration Approves LIB Therapeutics’ LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
LIB Therapeutics Announces Results from Late Breaking Science Presentation at 2025 American Heart Association Meeting in New Orleans November 9, 2025
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
06/05/2025
Eventi
Industria
Scienza
Sanità
Igiene alimentare
Medicina - Varie
Cardiologia
Biotecnologia
Farmaceutica
Salute
LIB Therapeutics Announces Key Results from Presentations at 2025 European Atherosclerosis Society Meeting in Glasgow May 5-6
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
10/02/2025
Scienza
Igiene alimentare
Salute
Medicina - Varie
Cardiologia
Biotecnologia
Farmaceutica
Industria
LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
27/01/2025
LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
16/12/2024
Scienza
Igiene alimentare
Salute
Medicina - Varie
Cardiologia
Biotecnologia
Sanità
Farmaceutica
Industria
LIB Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults with Elevated LDL-Cholesterol
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0
18/11/2024
Cardiologia
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Industria
LIB Therapeutics Announce Positive Results from Lerodalcibep 72-Week Open-Label Extension Studies at American Heart Association 2024
Fonte
LIB Therapeutics Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0